GS-9224

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H16ClF2N3O4S
Molecular Weight	467.874
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C1=C2C=CC=NC2=C(O)C3=C1CN(CC4=C(F)C=C(F)C(Cl)=C4)C3=O)S(C)(=O)=O

InChI

InChIKey=NOOXOJVRDAFYDD-UHFFFAOYSA-N

InChI=1S/C20H16ClF2N3O4S/c1-25(31(2,29)30)18-11-4-3-5-24-17(11)19(27)16-12(18)9-26(20(16)28)8-10-6-13(21)15(23)7-14(10)22/h3-7,27H,8-9H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C20H16ClF2N3O4S
Molecular Weight	467.874
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Tue Apr 01 18:12:46 GMT 2025` Edited by `admin` on `Tue Apr 01 18:12:46 GMT 2025`
Record UNII	95NFK5HO9J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

METHANESULFONAMIDE, N-(7-((5-CHLORO-2,4-DIFLUOROPHENYL)METHYL)-7,8-DIHYDRO-9-HYDROXY-8-OXO-6H-PYRROLO(3,4-G)QUINOLIN-5-YL)-N-METHYL-

Preferred Name

English

GS-9224

Common Name

English

N-(7-((5-CHLORO-2,4-DIFLUORO-PHENYL)METHYL)-9-HYDROXY-8-OXO-6H-PYRROLO(3,4-G)QUINOLIN-5-YL)-N-METHYL-METHANESULFONAMIDE

Systematic Name

English

Code System Code Type Description

FDA UNII

95NFK5HO9J

Created by admin on Tue Apr 01 18:12:46 GMT 2025 , Edited by admin on Tue Apr 01 18:12:46 GMT 2025

PRIMARY

PUBCHEM

16097720

Created by admin on Tue Apr 01 18:12:46 GMT 2025 , Edited by admin on Tue Apr 01 18:12:46 GMT 2025

PRIMARY

EPA CompTox

DTXSID801102770

Created by admin on Tue Apr 01 18:12:46 GMT 2025 , Edited by admin on Tue Apr 01 18:12:46 GMT 2025

PRIMARY

CAS

915409-66-4

Created by admin on Tue Apr 01 18:12:46 GMT 2025 , Edited by admin on Tue Apr 01 18:12:46 GMT 2025

PRIMARY

Related Record Type Details


					95NFK5HO9J

GS-9224

ACTIVE MOIETY

Comments:

GS-9224, a backup compound to GS-9160, entered clinical trials in the fourth financial quarter of 2006. Following the results of a Phase I clinical study, however, Gilead Sciences announced the discontinuation of GS-9224 development due to an unexpected short half-life. To our knowledge, the structural details of GS-9224 have not yet been disclosed to the public.